TrialAmerican heart journal2017

A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial.

Manvir K Hayer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.